Skye Bioscience Investors Pressed to Seek Lead Role After Class Action Filing
Plaintiffs' firms are mobilizing after Skye’s October trial update drove a 60% one-day stock plunge.
Overview
- A securities class action has been filed on behalf of investors who bought Skye shares between November 4, 2024 and October 3, 2025.
- Investors have until January 16, 2026 to ask the court to be appointed lead plaintiff, and no class has been certified.
- Rosen Law Firm, Faruqi & Faruqi, Berger Montague, and Levi & Korsinsky issued notices inviting affected shareholders to contact them.
- The complaint alleges Skye misled investors by overstating the efficacy and clinical, regulatory, and commercial prospects of nimacimab.
- Skye’s October 6 topline Phase 2a update reported that the nimacimab monotherapy arm missed the primary weight-loss endpoint and showed lower-than-expected exposure, after which the stock closed down 60% at $1.90.